Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TAFASITAMAB-CXIX Cause Diffuse large b-cell lymphoma refractory? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Diffuse large b-cell lymphoma refractory have been filed in association with TAFASITAMAB-CXIX. This represents 0.7% of all adverse event reports for TAFASITAMAB-CXIX.

5
Reports of Diffuse large b-cell lymphoma refractory with TAFASITAMAB-CXIX
0.7%
of all TAFASITAMAB-CXIX reports
0
Deaths
0
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma refractory From TAFASITAMAB-CXIX?

Of the 5 reports.

Is Diffuse large b-cell lymphoma refractory Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB-CXIX. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does TAFASITAMAB-CXIX Cause?

Disease progression (218) Lymphoma (158) Off label use (126) Death (53) Drug ineffective (39) Blood lactate dehydrogenase increased (34) Diffuse large b-cell lymphoma (32) Malignant neoplasm progression (30) Neutropenia (30) Polyneuropathy (29)

What Other Drugs Cause Diffuse large b-cell lymphoma refractory?

RITUXIMAB (461) CYCLOPHOSPHAMIDE (360) DOXORUBICIN (345) VINCRISTINE (331) ETOPOSIDE (244) PREDNISONE (214) EPCORITAMAB-BYSP (198) CYTARABINE (193) DEXAMETHASONE (170) CISPLATIN (156)

Which TAFASITAMAB-CXIX Alternatives Have Lower Diffuse large b-cell lymphoma refractory Risk?

TAFASITAMAB-CXIX vs TAFINLAR TAFASITAMAB-CXIX vs TAFLUPROST TAFASITAMAB-CXIX vs TAGRAXOFUSP-ERZS TAFASITAMAB-CXIX vs TAHOR TAFASITAMAB-CXIX vs TALAZOPARIB

Related Pages

TAFASITAMAB-CXIX Full Profile All Diffuse large b-cell lymphoma refractory Reports All Drugs Causing Diffuse large b-cell lymphoma refractory TAFASITAMAB-CXIX Demographics